Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 12,598	$ 14,025
Accounts receivable, net of allowance for credit losses	2,149	1,906
Contract assets	2,226	1,604
Inventories	2,115	4,454
Other current assets	898	852
Total current assets	19,986	22,841
Property, plant and equipment, net	11,699	12,166
Other assets	1	18
Total assets	31,686	35,025
Current liabilities:
Accounts payable	679	1,203
Accrued expenses	2,236	1,765
Current maturities of long-term debt	87	81
Deposits from purchasers of MesoScribe assets – note 14		597
Contract liabilities	3,135	4,908
Total current liabilities	6,137	8,554
Long-term debt, net of current portion	181	268
Total liabilities	6,318	8,822
Commitments and contingencies (see note 15)
Stockholders’ equity:
Common stock - $0.01 par value – 20,000,000 shares authorized; issued and outstanding 6,881,838 at December 31, 2024 and 6,824,511 at December 31, 2023	69	68
Additional paid-in capital	29,757	28,695
Accumulated deficit	(4,458)	(2,560)
Total stockholders’ equity	25,368	26,203
Total liabilities and stockholders’ equity	$ 31,686	$ 35,025